JA
Therapeutic Areas
Moderna Pipeline
| Drug | Indication | Phase |
|---|---|---|
| mRNA-1345 | Respiratory Syncytial Virus (RSV) in adults ≥60 | Approved |
| mRNA-1083 | Combined Influenza + COVID-19 booster | Phase 3 |
| mRNA-1010/1011 | Seasonal Influenza | Phase 3 |
| mRNA-1647 & mRNA-1230 | Cytomegalovirus (CMV) prevention | Phase 3 |
| mRNA-4157 (V940) / KEYTRUDA® | Adjuvant treatment for high-risk melanoma (post-resection) | Approved |
| mRNA-6231 (AZURE™) | Autoimmune disorders (e.g., Systemic Lupus Erythematosus) | Phase 2 |
| mRNA-3927 | Propionic Acidemia (PA) | Phase 1/2 |